Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases.
Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases.
复制标题
肝移植受者和慢性肝病患者加强接种SARS-CoV-2疫苗后的抗体反应
DOI：
10.1016/j.aohep.2022.100702
复制
发表时间：
2022-07
影响因子：
3.8
通讯作者：
Thuluvath PJ
中科院分区：
文献类型：
--
作者：
Chauhan M;Nzeako I;Li F;Thuluvath PJ
据报道，在接受肝移植(LT)和慢性肝病(CLD)的患者中，接种SARS-CoV-2疫苗后抗体(Ab)反应较低。对于初次接种反应不佳的人，加强剂量的作用还没有很好的界定。在这项前瞻性研究中，我们测定了肝移植受者和对初始标准方案反应不佳的慢性肝病(CLD)伴或不伴肝硬变的患者在加强剂量后对Spike蛋白的抗体(Ab)反应。在纳入的80名患者中，45名患者患有肝移植，35名患者患有慢性肝病(18例合并肝硬变)。在标准方案完成后的中位数138.5天内给予加强剂量。加强剂量后，58例(73%，31例LT，27例CLD)反应良好(≥250U/mL)，22例(28%，14例LT，8例CLD)反应差(7例检测不到，15例抗体水平较低)。患者均未发生严重不良反应。标准免疫后抗体阴性者(80U/mL)的抗体反应率(42%)明显低于抗体水平较低者(0.80~249U/mL)(P=0.0001)。同种和异种加强免疫后的抗体反应相似。我们已经证明，加强剂量将增强LT接受者和那些在最初的疫苗方案后反应较差的CLD患者的抗体反应。
Lower antibody (Ab) responses after SARS-CoV-2 vaccination have been reported in liver transplant (LT) recipients and those with chronic liver diseases (CLD). The role of a booster dose in those with poor responses to initial vaccination is not well defined. In this prospective study, we determined antibody (Ab) response to spike protein after a booster dose in LT recipients and those with chronic liver diseases (CLD) with and without cirrhosis after they had a poor response to an initial standard regimen. Of the 80 patients enrolled, 45 had LT, and 35 had CLD (18 with cirrhosis). A booster dose was given at a median of 138.5 days after the completion of the standard regimen. After the booster dose, 58 (73%, 31 LT, 27 CLD) had good response (≥250 U/mL), and 22 (28%, 14 LT, and 8 CLD) had poor response (7 undetectable and 15 with low Ab levels). No patient had any serious adverse events. The antibody responses were lower in those who had undetectable Ab (80 U/mL) than those who had low levels of Ab (0.80-249 U/mL) after the standard vaccination regimen (42% vs. 87%, p=0.0001). The antibody responses after homologous and heterologous booster doses were similar. We have shown that a booster dose will enhance Ab responses in LT recipients and those with CLD who had poor responses after an initial vaccine regimen.
登录
查看更多内容
影响因子：
9.4
作者：
Higgins V;Fabros A;Kulasingam V
通讯作者：
Kulasingam V
影响因子：
25.7
作者：
Rabinowich L;Grupper A;Baruch R;Ben-Yehoyada M;Halperin T;Turner D;Katchman E;Levi S;Houri I;Lubezky N;Shibolet O;Katchman H
通讯作者：
Katchman H
影响因子：
64.8
作者：
Pozzetto, Bruno;Legros, Vincent;Trouillet-Assant, Sophie
通讯作者：
Trouillet-Assant, Sophie
影响因子：
8.8
作者：
Grupper, Ayelet;Rabinowich, Liane;Katchman, Helena
通讯作者：
Katchman, Helena
维持性血液透析患者对辉瑞 BNT162b2 疫苗加强剂的体液反应。
影响因子：
4.2
作者：
通讯作者：
--